Objective Biotechnology Launches First-Ever Automated Microinjection Robot for Genetic Research
Microinjection is an essential but slow step in genetic research, traditionally requiring technicians to manually align and inject each embryo with precision. The Autoinjector transforms this process by combining computer vision and machine learning, delivering consistent, high-precision injections up to four times faster than manual methods—while reducing training time from months to weeks.
The Autoinjector also enables entirely new high-throughput experiments that aren't feasible by hand. In the study published in GENETICS, researchers used it to inject over 20,000 uniquely barcoded DNA plasmids into 1,700 Drosophila embryos in just two days—generating more than 400 unique transgenic lines and, for the first time, allowing scientists to measure how many independent germline integrations occurred per embryo. The study also demonstrated that the Autoinjector significantly improved vitrification rates and post-thaw survival of zebrafish, outperforming traditional manual injection.
'The system has already demonstrated success in gene editing and transgenesis experiments across both insect and vertebrate models at multiple early-access sites,' said James Grabau, CEO of Objective Biotechnology. 'The Autoinjector is designed to remove a stubborn and persistent bottleneck in the process of generating transgenic models in a variety of species and applications.'
'The Autoinjector comes pre-loaded with injection protocols for commonly used model organisms such as Drosophila and zebrafish, and it can be fully customized for emerging or non-model species,' said Daryl Gohl, Chief Scientific Officer of Objective Biotechnology. 'This flexibility makes the Autoinjector particularly valuable for labs working across multiple species, providing them with the ability to streamline both basic and applied genetic research.'
Objective Biotechnology is a leader in developing innovative solutions for genetic engineering and neurotechnology. Its mission is to accelerate discovery by equipping scientists with cutting-edge tools that simplify, scale, and expand what's possible in modern genetics and neuroscience.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
44 minutes ago
- Business Wire
Figma and Motiff Reach Global Settlement in Intellectual Property Protection Lawsuits
SAN FRANCISCO--(BUSINESS WIRE)-- Figma and Motiff announced today that the companies have reached an agreement to resolve their intellectual property disputes in the U.S. and Singapore. Under the settlement agreement, Motiff will cease selling its current Motiff Editor Tool and will not sell any future products derived from it, globally, with the exception of mainland China. In September 2024, Figma filed a U.S. lawsuit for breach of contract and copyright infringement against Motiff and its affiliates. On the same day that Figma filed its U.S. suit, it also sued Motiff in Singapore for copyright infringement and trademark infringement. Figma and Motiff have mutually agreed to settle both lawsuits. Under the settlement agreement, Motiff will cease selling its current Motiff Editor Tool and will not sell any future products derived from it, globally, with the exception of mainland China. In mainland China, Motiff may continue to sell its current Motiff Editor Tool for one year, while it reengineers and redesigns the product. Motiff has also agreed to reimburse Figma's legal expenses. 'Figma is singularly focused on building the best possible product for our users. We welcome fair competition and strongly believe that no one should be allowed to copy our or others' IP to gain an advantage. We are pleased to have reached a global settlement that aligns with Figma's values and allows us to keep building for our customers and community without distraction,' said a Figma spokesperson. 'Motiff is equally pleased to have reached a compromise global settlement with Figma that will allow us to focus our efforts on Motiff's AI 2.0 product. Motiff is committed to bringing AI value to our users,' said a Motiff spokesperson. The agreement took effect on July 23, 2025.
Business Wire
an hour ago
- Business Wire
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
DUBLIN--(BUSINESS WIRE)-- Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: 'Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes.' Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: 'Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD.' Elaine Mac Hale, Clinical Operations Director, added: 'Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care.' Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.
CBS News
2 hours ago
- CBS News
Trusty K-9 companion suiting up to keep University of Minnesota medical student safe
A dog named Nova is suiting up for a very special purpose: keeping a close eye on her human, University of Minnesota medical student Wesley Flint. "Everyday we come in and I put on her boots and her lab coat and her goggles," Flint said. It's all part of Nova's personal protection equipment (PPE) routine as Flint's trusted assistant. Nova is led to her work space, a plush mat under a nearby table, and patiently waits until she's needed. "She's my medical alert dog. I'm a Type-1 diabetic," Flint said. "Diabetic alert dogs can actually smell the change in your blood sugar before any glucose sensor can pick it up a lot of the time." Sometimes, Nova can sense a blood-sugar drop up to a half hour before Flint's arm sensor does. "When my blood sugar is low, she'll get off the mat and come over to me and head butt me against the thigh," Flint said. "If she gives me an alert, I can check my sensor to see which way I'm trending. She's pretty accurate. Pretty rare for her to be wrong." Is Flint worried about technology or AI replacing Nova some day? "I don't think AI has a nose yet, and I'm not sure we can manufacture a robotic nose sensitive enough," Flint said.
